News & Updates

A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.

Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.

Individuals with asthma may benefit from a behavioural intervention to increase their physical activity (PA), which may lead to improvements in quality of life and sleep, as well as a reduction in asthma and anxiety symptoms, suggest the results of a recent study.

Among patients with rheumatoid arthritis (RA), those with clinically active RA, cardiovascular or cerebrovascular disease (CVD), hypertension, depression, and anxiety are at greater risk of dementia, reveals a study. Among CVD events, ischaemic stroke and heart failure are significantly associated with an increased dementia risk.

Septal reduction therapies (SRT) lower the readmission rates for heart failure (HF) in Medicare patients with obstructive hypertrophic cardiomyopathy (oHCM), a study has shown.

A fully closed-loop insulin delivery system, also known as artificial pancreas, helps improve the management of type 2 diabetes in adults, increasing the time spent in target glucose range by 8 hours per day without promoting hypoglycaemic events as compared with standard insulin therapy, as reported in a study.